Disc Medicine, Inc. (IRON)
(Delayed Data from NSDQ)
$51.74 USD
+1.39 (2.76%)
Updated Sep 9, 2024 04:00 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IRON 51.74 +1.39(2.76%)
Will IRON be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IRON based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IRON
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
Disc Medicine (IRON) Down on Mixed Results From AURORA Study
IRON: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in Disc Medicine, Inc. (IRON)? Wall Street Analysts Think 38.17%
Recent Price Trend in Disc Medicine, Inc. (IRON) is Your Friend, Here's Why
Here's Why Disc Medicine, Inc. (IRON) Is a Great 'Buy the Bottom' Stock Now
Other News for IRON
Disc Medicine to Participate in Upcoming Investor Conferences
TJX downgraded, Crocs upgraded: Wall Street's top analyst calls
Disc Medicine initiated with bullish view at Wells Fargo, here's why
Disc Medicine Breaks Above 200-Day Moving Average - Bullish for IRON
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Natera (NTRA) and Disc Medicine (IRON)